Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

Autor: Parker, Christopher C, James, Nicholas D, Brawley, Christopher D, Clarke, Noel W, Hoyle, Alex P, Ali, Adnan, Ritchie, Alastair W S, Attard, Gerhardt, Chowdhury, Simon, Cross, William, Dearnaley, David P, Gillessen, Silke, Gilson, Clare, Jones, Robert J, Langley, Ruth E, Malik, Zafar I, Mason, Malcolm D, Matheson, David, Millman, Robin, Russell, J Martin, Thalmann, George N, Amos, Claire L, Alonzi, Roberto, Bahl, Amit, Birtle, Alison, Din, Omar, Douis, Hassan, Eswar, Chinnamani, Gale, Joanna, Gannon, Melissa R, Jonnada, Sai, Khaksar, Sara, Lester, Jason F, O'Sullivan, Joe M, Parikh, Omi A, Pedley, Ian D, Pudney, Delia M, Sheehan, Denise J, Srihari, Narayanan Nair, Tran, Anna T H, Parmar, Mahesh K B, Sydes, Matthew R
Zdroj: The Lancet; December 2018, Vol. 392 Issue: 10162 p2353-2366, 14p
Abstrakt: Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that the benefit would be greatest in patients with a low metastatic burden. We aimed to compare standard of care for metastatic prostate cancer, with and without radiotherapy.
Databáze: Supplemental Index